Adjusted analyses associated overestimation with nearly doubled 2-year mortality (aHR 1.98; 95% CI, 1.04-3.77). Differences in advanced-therapy receipt did not explain the mortality signal, suggesting ...
A secondary analysis of the SOUL trial shows significant improvement in heart failure outcomes with oral semaglutide vs placebo, consistent with the injectable formulation.
Patients with acute decompensated heart failure (ADHF) have significant differences according to left ventricular ejection fraction, according to a study recently published in BMC Cardiovascular ...
Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported late breaking echocardiography results from its Phase ...
Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.
Patients with newly diagnosed heart failure with reduced ejection fraction (HFrEF) commonly have improvements in their LVEF, but that doesn’t mean they can let their guard down, data from a large ...
Withdrawing renin-angiotensin inhibitors/angiotensin receptor-neprilysin inhibitors and mineralocorticoid receptor antagonists tied to higher one-year mortality, morbidity. HealthDay News — In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results